Can Semaglutide Cause Kidney Stones?

    By Trimi Medical Team5 min read

    Semaglutide does not directly cause kidney stones. Kidney stones are not listed as a side effect in the prescribing information for semaglutide (Ozempic, Wegovy). However, the reduced fluid intake, nausea, and occasional vomiting that occur during GLP-1 treatment can lead to dehydration, which is a well-established risk factor for kidney stone formation.

    Medical Disclaimer: This article is for informational purposes only. If you experience severe flank pain, blood in urine, or symptoms of kidney stones, seek medical attention promptly.

    The Indirect Connection: Dehydration

    The primary link between semaglutide and kidney stone risk is dehydration. Semaglutide can contribute to dehydration in several ways:

    • Reduced appetite leads to less fluid intake: Many patients forget to drink when they are not eating, since meals are often when people consume a significant portion of their daily fluids.
    • Nausea and vomiting: GI side effects, particularly during dose titration, can cause fluid loss.
    • Diarrhea: Some patients experience diarrhea, leading to additional fluid and electrolyte loss.

    Concentrated urine from dehydration allows minerals like calcium, oxalate, and uric acid to crystallize, forming kidney stones. This risk exists regardless of the cause of dehydration.

    Semaglutide and Kidney Health: The Bigger Picture

    Emerging research actually suggests semaglutide may be beneficial for kidney health in several ways:

    • Weight loss reduces kidney disease risk: Obesity is a major risk factor for chronic kidney disease. The weight loss achieved with semaglutide may be protective.
    • Blood sugar improvement: Better glycemic control reduces diabetic nephropathy progression.
    • Blood pressure reduction: Semaglutide-associated weight loss often lowers blood pressure, which benefits kidney function.
    • Direct renal effects: Some studies suggest GLP-1 receptor agonists may have direct anti-inflammatory and anti-fibrotic effects in the kidneys, though this research is still evolving.

    Prevention Strategies

    • Drink at least 64 oz (8 cups) of water daily, even if you don't feel thirsty.
    • Set hydration reminders on your phone, especially during early treatment when appetite is most suppressed.
    • Monitor urine color: Pale yellow indicates adequate hydration. Dark yellow or amber signals dehydration.
    • Replace electrolytes if you experience vomiting or diarrhea.
    • Limit high-oxalate foods if you have a history of calcium oxalate stones (spinach, rhubarb, nuts, chocolate).
    • Report persistent vomiting to your provider, as this may warrant dose adjustment.

    Frequently Asked Questions

    Can semaglutide cause kidney stones?

    Semaglutide does not directly cause kidney stones. However, dehydration from reduced fluid intake, nausea, or vomiting during treatment can increase kidney stone risk indirectly. Staying well hydrated is the best prevention.

    Is semaglutide safe for kidneys?

    Yes, semaglutide is generally safe for kidneys and may even have protective effects through weight loss and improved metabolic health. However, severe dehydration from vomiting or inadequate fluid intake can cause acute kidney injury in rare cases.

    How much water should you drink on semaglutide?

    Aim for at least 64 ounces (8 cups) of water daily, and more if you exercise, live in a hot climate, or experience GI side effects. Monitor your urine color as a practical hydration indicator.

    For monitored GLP-1 treatment with hydration and nutrition guidance, explore Trimi's treatment programs.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 15, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Semaglutide has a half-life of about 7 days and takes approximately 5-7 weeks to fully clear your system after the last dose. Learn what this means for side effects and transitions.

    FDA approved oral Wegovy (semaglutide 50mg tablet) for weight loss in 2026. Review covers clinical trial results (~15% body weight loss), dosing, side effects, cost ($1,000–$1,500/mo), and affordable injectable alternatives.

    Complete guide to using Ozempic for weight loss. Learn about off-label prescribing, Ozempic vs Wegovy dosing differences, insurance, and why compounded semaglutide may be a better option.

    Complete guide to semaglutide 1.7mg dosing. Learn about expected weight loss results, side effects at this higher dose, and how to decide between staying at 1.7mg or advancing to 2.4mg.

    Start your GLP-1 journey — from $99/mo

    Get Started